Ownership and insider activity for Neurocrine Biosciences, Inc. (NBIX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages.
Price
| Price | $141.84 |
| Market Cap | $14.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-11 | Onyia Jude | A-Award | 3,587 | |
| 2026-09-11 | Onyia Jude | F-InKind | 1,936 | $302K |
| 2026-09-11 | Lippoldt Darin | A-Award | 4,483 | |
| 2026-09-11 | Lippoldt Darin | F-InKind | 2,419 | $378K |
| 2026-09-11 | Keswani Sanjay Chandru | A-Award | 3,914 | |
| 2026-09-11 | Keswani Sanjay Chandru | F-InKind | 2,112 | $330K |
| 2026-09-11 | GORMAN KEVIN CHARLES | A-Award | 14,343 | |
| 2026-09-11 | GORMAN KEVIN CHARLES | F-InKind | 7,839 | $1.2M |
| 2026-09-11 | Gano Kyle | A-Award | 6,275 | |
| 2026-09-11 | Gano Kyle | A-Award | 1,842 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $83.3M | $254.7M | $141.7M | $112.3M | $187.1M | $340.8M | $262.9M | $251.1M | $233.0M | $713.0M |
| Short-term Investments | $224.1M | $261.2M | $509.2M | $558.2M | $613.9M | $370.5M | $726.4M | $780.5M | $843.1M | $767.4M |
| Receivables | 0 | $31.1M | $57.4M | $126.6M | $157.1M | $185.5M | $350.0M | $439.3M | $479.1M | $686.8M |
| Inventory | 0 | $1.0M | $10.9M | $17.3M | $28.0M | $30.5M | $35.1M | $38.3M | $57.4M | $69.0M |
| Total Current Assets | $310.4M | $554.9M | $737.8M | $831.0M | $1.02B | $972.8M | $1.45B | $1.61B | $1.72B | $2.52B |
| Property, Plant & Equipment | $6.3M | $10.8M | $33.9M | $116.2M | $127.4M | $155.8M | $145.6M | $347.3M | $592.0M | $545.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | $37.2M | $35.5M | $36.5M | 0 |
| Total Assets | $365.1M | $817.6M | $993.2M | $1.31B | $1.73B | $2.07B | $2.37B | $3.25B | $3.72B | $4.63B |
| Accounts Payable | $5.1M | $5.6M | $38.4M | $41.4M | $39.4M | $51.5M | $67.3M | $133.3M | $99.9M | $104.9M |
| Short-term Debt | 0 | 0 | 0 | $408.8M | 0 | 0 | $169.4M | $170.1M | 0 | 0 |
| Total Current Liabilities | $30.4M | $54.4M | $88.2M | $565.3M | $186.5M | $245.8M | $537.7M | $654.8M | $507.7M | $743.4M |
| Long-term Debt | 0 | $369.6M | $388.5M | 0 | $317.9M | $335.1M | 0 | 0 | 0 | 0 |
| Total Liabilities | $50.2M | $445.5M | $512.4M | $669.1M | $608.5M | $698.5M | $660.9M | $1.02B | $1.13B | $1.38B |
| Retained Earnings | -$1.06B | -$1.20B | -$1.18B | -$1.13B | -$725.4M | -$635.8M | -$406.8M | -$157.1M | $29.2M | $447.7M |
| Total Equity | $314.9M | $372.1M | $480.8M | $636.9M | $1.13B | $1.37B | $1.71B | $2.23B | $2.59B | $3.25B |
| Total Debt | 0 | $369.6M | $388.5M | $495.5M | $412.3M | $440.4M | $262.9M | $428.4M | $455.1M | $415.3M |
| Net Debt | -$307.4M | -$146.3M | -$262.4M | -$175.0M | -$388.7M | -$270.9M | -$726.4M | -$603.2M | -$621.0M | -$1.07B |
| Working Capital | $280.0M | $500.5M | $649.5M | $265.7M | $829.7M | $727.0M | $915.8M | $952.2M | $1.22B | $1.78B |
Financial Health
| Debt / Equity | 0.11 |
| Current Ratio | 1.87 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 7.80 |
Profitability
| Return on Equity | 21.13% |
| Return on Invested Capital | 13.20% |
| Return on Assets | 13.16% |
| Gross Margin | 97.97% |
| Operating Margin | 23.38% |
| Net Margin | 20.91% |
Related companies: COO · ELAN · ICLR · RDY · SMMT · SNN
Explore sector: Healthcare · Biotechnology
More sections of NBIX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks